Table 2 Pathology and treatment of patients undergoing pancreatic surgery before and during the COVID lockdown period
Before lockdown | ||||||
|---|---|---|---|---|---|---|
2017/2018 | 2018/2019 | 2019/2020 | Total | Lockdown | p value | |
Tumor localization (%) | ||||||
Number | 254 | 253 | 232 | 739 | 242 | |
Pancreas | 200 (78.7) | 219 (86.6) | 179 (77.2) | 598 (80.9) | 197 (81.4) | 0.925 |
Papilla | 17 (6.7) | 12 (4.7) | 24 (10.3) | 53 (7.2) | 16 (6.6) | 0.885 |
Common bile duct | 10 (3.9) | 10 (4.0) | 12 (5.2) | 32 (4.3) | 13 (5.4) | 0.483 |
Duodenum | 27 (10.6) | 12 (4.7) | 17 (7.3) | 56 (7.6) | 16 (6.6) | 0.672 |
Pathology (%) | ||||||
Adenocarcinoma | 172 (85.0) | 173 (68.4) | 167 (72.0) | 512 (69.3) | 172 (71.1) | 0.629 |
Neuroendocrine | 19 (7.5) | 19 (7.5) | 12 (5.2) | 50 (6.8) | 19 (7.9) | 0.564 |
Other malignancy | 10 (3.9) | 9 (3.6) | 6 (2.5) | 25 (3.4) 11 (4.6) | 0.431 | |
IPMN | 33 (13.0) | 16 (6.3) | 21 (9.1) | 70 (9.5) 18 (7.4) | 0.367 | |
Other benign | 20 (7.9) | 36 (14.2) | 26 (11.2) | 82 (11.1) | 22 (9.1) | 0.403 |
Tumor stage Adenocarcinoma (%) | ||||||
0 | 3 (1.7) | 4 (2.3) | 3 (1.8) | 17 (3.3) | 2 (1.2) | 0.186 |
1 | 8 (4.7) | 23 (13.3) | 27 (16.2) | 79 (15.4) | 23 (13.3) | 0.716 |
2 | 73 (42.4) | 52 (30.1) | 54 (32.3) | 183 (35.7) | 53 (30.8) | 0.387 |
3 | 66 (38.4) | 63 (36.4) | 67 (40.1) | 205 (40.0) | 83 (48.3) | 0.061 |
4 | 22 (12.8) | 31 (17.9) | 16 (9.6) | 70 (13.6) | 23 (13.4) | 0.999 |
Operation (%) | ||||||
Whipple | 135 (53.2) | 97 (38.3) | 115 (49.6) | 347 (47.0) | 98 (40.5) | 0.087 |
Total pancreatectomy | 30 (11.8) | 52 (20.6) | 38 (16.4) | 120 (16.2) | 42 (17.4) | 0.691 |
Distal Pancreatectomy | 45 (17.7) | 52 (20.6) | 46a (19.8) | 143 (19.4) | 56b (23.1) | 0.411 |
Exploration | 44 (17.3) | 52 (20.6) | 33 (14.2) | 129 (17.5) | 46 (19.0) | 0.876 |
Adjuvant chemotherapy adenocarcinomas (%) | 117 (68.0) | 132 (76.3) | 118 (70.7) | 367 (71.7) | 125 (72.7) | 0.263 |